Stock listing

BOATS:ABSI Absci Corporation Stock

US listing (BOATS) of Absci Corporation · home listing NASDAQ:ABSI

Follow Absci Corporation into a list and get an email when it puts out news.

Home listing price · NASDAQ:ABSI

$7.51 USD -0.67 (-8.2%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ABSI

Past year +171.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$7.45 – $8.14 USDNov 20, 2026
Volume
4.74M sharesNov 20, 2026
Market cap
$1.30B USDAt the close on Nov 20, 2026 · price × 172.7M shares outstanding
52-week range
$2.24 – $12.54 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$38.24M USDMedian day 3.56M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Absci Corporation logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ABSI · Home$7.51 USD-0.67 (-8.2%)4,744,482$7.91$8.14$7.45$8.18Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ABSI · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$7.51-0.67-8.2%$7.91$8.14$7.454,744,482
$8.18+0.60+7.9%$7.60$8.73$7.605,664,227
$7.58+0.105+1.4%$7.57$7.79$7.344,691,970
$7.475-0.975-11.5%$8.15$8.15$7.297,867,474
$8.45-0.685-7.5%$9.36$9.40$8.325,474,245
$9.135-0.985-9.7%$9.47$9.94$8.964,910,926
$10.12+0.15+1.5%$10.48$10.48$9.7155,378,419
$9.97-0.83-7.7%$10.44$10.91$9.6754,102,369
$10.80+0.63+6.2%$10.10$11.22$9.923,750,490
$10.17+0.78+8.3%$9.83$10.26$9.514,149,657
$9.39-1.09-10.4%$10.03$10.13$9.005,112,175
$10.48+0.48+4.8%$10.26$10.68$9.784,151,767
$10.00+0.31+3.2%$10.03$10.66$9.852,713,927
$9.69-1.44-12.9%$11.29$11.32$9.683,787,828
$11.13-0.97-8.0%$11.41$11.80$10.454,557,919
$12.10+0.22+1.9%$11.91$12.54$11.914,303,126
$11.88+1.31+12.4%$10.47$11.89$10.435,805,907
$10.57+1.12+11.9%$9.61$10.95$9.365,814,853
$9.45+0.27+2.9%$9.19$9.76$9.033,360,259
$9.18-0.19-2.0%$9.28$9.35$8.9651,888,993
$9.37-0.67-6.7%$9.69$9.95$8.933,704,869
$10.04+0.97+10.7%$9.24$10.20$9.1145,346,252
$9.07+0.53+6.2%$8.50$9.10$8.222,788,843
$8.54+0.29+3.5%$8.69$8.96$8.3952,757,646
$8.25-0.63-7.1%$8.93$8.95$8.123,551,075
$8.88+0.14+1.6%$8.43$8.945$8.233,395,649
$8.74-0.36-4.0%$8.88$9.12$8.623,557,567
$9.10-0.57-5.9%$9.445$9.66$9.003,042,600
$9.67-0.49-4.8%$10.07$10.09$9.432,860,500
$10.16+1.22+13.6%$9.20$10.39$8.934,241,800
$8.94-0.28-3.0%$9.04$9.27$8.814,681,700
$9.22-1.05-10.2%$10.00$10.22$9.125,850,900
$10.27-1.26-10.9%$11.77$11.89$10.215,876,200
$11.53+0.46+4.2%$11.11$11.80$10.874,294,900
$11.07+0.32+3.0%$11.14$11.35$10.833,380,300
$10.75-0.02-0.2%$10.80$11.27$10.554,605,100
$10.77+0.63+6.2%$10.36$10.99$10.045,428,100
$10.14+0.65+6.8%$9.59$10.18$9.4853,423,500
$9.49-0.25-2.6%$9.57$9.669$9.253,251,500
$9.74-0.605-5.8%$10.49$10.50$9.683,206,600
$10.35+0.60+6.2%$9.55$10.39$9.303,385,300
$9.745-0.965-9.0%$10.51$10.62$9.474,715,100
$10.71+0.89+9.1%$10.00$11.26$9.758,360,900
$9.82+0.17+1.8%$10.06$10.15$9.504,556,400
$9.65+0.38+4.1%$9.27$9.74$9.087,729,600
$9.27+1.23+15.3%$8.295$9.83$8.2858,659,400
$8.04+0.10+1.3%$8.02$8.20$7.8652,613,200
$7.94-0.15-1.9%$8.055$8.07$7.792,341,800
$8.09-0.12-1.5%$8.03$8.25$8.022,999,800
$8.21-0.03-0.4%$8.42$8.57$8.111,965,800
$8.24-0.41-4.7%$8.375$8.56$8.023,084,800
$8.65-0.26-2.9%$8.89$9.02$8.6252,030,300
$8.91+0.09+1.0%$8.82$9.10$8.572,506,600
$8.82+0.02+0.2%$8.69$9.03$8.652,150,200
$8.800.000.0%$8.91$8.995$8.552,746,300
$8.80-0.04-0.5%$8.90$9.23$8.362,946,900
$8.84-0.20-2.2%$8.85$9.08$8.7113,235,100
$9.04+0.33+3.8%$8.67$9.09$8.625,257,200
$8.71-0.71-7.5%$9.202$9.30$8.602,506,100
$9.42+0.20+2.2%$9.28$9.679$9.1553,210,200
$9.22-0.41-4.3%$9.555$9.65$8.902,674,100
$9.63+0.79+8.9%$9.11$9.705$9.102,339,877
$8.84-0.71-7.4%$9.33$9.36$8.752,203,547
$9.55+0.27+2.9%$9.56$9.90$9.502,331,000
$9.28-0.71-7.1%$9.74$10.03$9.242,909,300
Ticker
BOATS:ABSI
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BOATS
Currency
USD

What changed lately

Latest news

All Absci Corporation news

Absci Corporation on 6ix

Sector
Health care
Industry
Biotechnology
News releases
17 in the last 12 months · 124 in all · newest Nov 12, 2026 · oldest 2021
Calls
12 calls with a replay · 12 with a transcript · latest Nov 12, 2026
Decks
16 decks · latest Nov 12, 2026

Where Absci Corporation is listed

ListingExchangeCountryCurrency
NASDAQ:ABSI · Home listingNASDAQUnited StatesUSD
BOATS:ABSI · This pageBOATSUnited StatesUSD

Valuation

EV/sales 758× against a median of 21.3×: 8th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.13B USD
P/E
Loss
EV/sales
758×
EV/EBITDA
Negative EBITDA
Price/book
5.9×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
3.20

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Absci Corporation · NASDAQ:ABSIUS$1.30BUS$1.13Bn/a758×n/a5.9×n/a0.0×3.20
Immunocore Holdings plc · NASDAQ:IMCRUS$1.36BUS$463.6Mn/a1.1×n/a3.3×−7.5%0.0×0.62
Nanobiotix SA · EURONEXT:NANOUS$1.36BUS$1.36Bn/a41.7×n/an/a−80.8%n/an/a
uniQure N.V. · NASDAQ:QUREUS$1.36BUS$739.1Mn/a36.6×n/a4.6×n/a0.2×1.25
UroGen Pharma Ltd. · NASDAQ:URGNUS$1.36BUS$1.46Bn/a5.8×n/an/a−26.3%n/a1.23
OliX Pharmaceuticals, Inc. · KRX:226950US$1.31BUS$1.16Bn/a114×n/a7.4×−102.9%0.1×n/a
Avalyn Pharma Inc. · NASDAQ:AVLNUS$1.26BUS$946.4Mn/an/an/a3.4×n/a0.0×0.12
LB Pharmaceuticals Inc · NASDAQ:LBRXUS$1.26BUS$858.7Mn/an/an/a3.0×n/a0.0×0.81
MannKind Corporation · NASDAQ:MNKDUS$1.24BUS$1.46Bn/a3.5×309×n/a−18.1%n/a1.06
Novavax, Inc. · NASDAQ:NVAXUS$1.23BUS$902.3Mn/a2.2×n/an/a−18.6%n/a1.98
Silence Therapeutics PLC · NASDAQ:SLNUS$1.23BUS$984.6Mn/a2,159×n/a5.7×n/a0.0×1.07
Median of the othersUS$1.28BUS$965.5M21.3×309×4.0×−22.4%0.0×1.07

Forecasts

9 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
14.73 USD · Analysts' mean
EPS, year to Dec 2026
-0.78 · 2 analysts
Revenue, year to Dec 2026
3.72M · 11 analysts

Team and board

Officers

OfficerRole
Sean McClainFounder, CEO & Director
Zach JonassonChief Financial Officer & Chief Business Officer
Mary SzelaPresident, TriSalus Life Sciences
Shelby WalkerChief Legal Officer
Alex KhanVPFinance & Investor Relations
Alexander KhanCVP, Finance & Investor Relations
ContactAlex KhanVPFinance & Investor Relations
Christine LemkeSVP, Portfolio and Growth Strategy
Daniel RabinovitsjVice President, Meta
Douglas Ganini da SilvaVP, Biologics Discovery & Research
Jeanne SchreuderSVP, People & Experience
Michael MangoneVP, Business Development
Moetaz AlbizemSVP, Clinical Operations
Todd BedrickSVP, Chief Accounting Officer
Gerry MuhleChief Commercial Officer
Ransi SomaratneChief Medical Officer
Wen ShaChief of Staff

Board

DirectorRole
Sean McClainFounder, CEO & Director

Events

Calls

CallWhenStatus
Absci (NASDAQ:ABSI) Q3 2026 Earnings CallThu, Nov 12, 2026 · 8:00 AM ETReplay
Absci (NASDAQ:ABSI) Q2 2026 Earnings CallTue, Aug 11, 2026 · 4:30 PM ETReplay
Absci (NASDAQ:ABSI) Q1 2026 Earnings CallThu, May 07, 2026 · 4:30 PM ETReplay
Absci (NASDAQ:ABSI) Q4 2025 Earnings CallTue, Mar 24, 2026 · 4:30 PM ETReplay
Absci (NASDAQ:ABSI) Q3 2025 Earnings CallWed, Nov 12, 2025 · 4:30 PM ETReplay
Absci (NASDAQ:ABSI) Q2 2025 Earnings CallTue, Aug 12, 2025 · 4:30 PM ETReplay
Absci (NASDAQ:ABSI) Q1 2025 Earnings CallTue, May 13, 2025 · 4:30 PM ETReplay
Absci (NASDAQ:ABSI) Q4 2024 Earnings CallTue, Mar 18, 2025 · 4:30 PM ETReplay
Absci (NASDAQ:ABSI) Q3 2024 Earnings CallTue, Nov 12, 2024 · 8:00 AM ETReplay
Absci (NASDAQ:ABSI) Q2 2024 Earnings CallWed, Aug 14, 2024 · 4:30 PM ETReplay
All 12 calls
CallWhenStatus
Absci (NASDAQ:ABSI) Q1 2024 Earnings CallTue, May 14, 2024 · 8:00 AM ETReplay
Absci (NASDAQ:ABSI) Q3 2021 Earnings CallTue, Nov 09, 2021 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 12, 2026 · Before open−9.7%
Q2 2026Aug 11, 2026 · After close+1.0%
Q1 2026May 7, 2026 · After close+2.6%
Q4 2025Mar 24, 2026−0.3%
Q3 2025Nov 12, 2025 · After close−22.4%
Q2 2025Aug 12, 2025 · After close+5.0%
Q1 2025May 13, 2025 · After close−1.7%
Q4 2024Mar 19, 2025 · Before open−3.3%
Q3 2024Nov 12, 2024 · Before open−14.9%
Q2 2024Aug 14, 2024 · After close+11.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · Before open−4.5%
Q4 2023Mar 21, 2024 · Before open+3.7%
Q3 2023Nov 14, 2023 · After close0.0%
Q2 2023Aug 14, 2023 · Before open+5.4%
Q1 2023May 15, 2023 · After close−8.6%
Q4 2022Mar 30, 2023 · After close+4.2%
Q3 2022Nov 9, 2022 · Before open+3.3%
Q2 2022Aug 11, 2022 · Before open+14.1%
Q1 2022May 11, 2022 · Before open−12.8%
Q4 2021Mar 22, 2022 · After close+0.7%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck61 slidesNov 12, 2026
Investor Presentation (September 2026)Investor deck60 slidesSeptember 2026
Investor Presentation (May 2026)Investor deck58 slidesMay 7, 2026
Investor Presentation (March 2026)Investor deck79 slidesMar 24, 2026
Jefferies Healthcare Conference (2026)Conference23 slides2026
2026 J.P. Morgan Healthcare ConferenceConference23 slidesJanuary 2026
Goldman Sachs 47th Annual Global Healthcare Conference (2026)Conference24 slides2026
Investor Presentation (November 2025)Investor deck84 slidesNov 12, 2025
Investor Presentation (August 2025)Investor deck74 slidesAug 12, 2025
Corporate Update (May 2025)Corporate update41 slidesMay 13, 2025
All 16 decks
DeckKindSlidesDate
Investor Presentation (March 2025)Investor deck67 slidesMar 18, 2025
2025 J.P. Morgan Healthcare ConferenceConference24 slidesJan 15, 2025
Technical Presentation (2025)Technical35 slides2025
Investor Presentation (November 2024)Investor deck49 slidesNov 12, 2024
Investor Presentation (August 2024)Investor deck49 slidesAug 14, 2024
42nd J.P. Morgan Healthcare Conference (January 2024)Conference22 slidesJanuary 2024

Open Decks

Financings

RaiseDate
Public offering of common stock
Announced: about US$100M · US$7.41 a share · Jefferies +3
Dealers: Jefferies (co-lead), J.P. Morgan (co-lead), TD Cowen (co-lead), Guggenheim Securities (co-lead)
Buyers: Eli Lilly & Company; Adage; BVF Partners; Columbia Threadneedle; Invus; Redmile
Use of proceeds: Advance ABS-201 anti-PRLR antibody in androgenetic alopecia and endometriosis, plus working capital and general corporate purposes
Jun 24, 2026
Public offering of common stock
Announced: US$50M · US$3 a share · Morgan Stanley +4
Dealers: Morgan Stanley (co-lead), J.P. Morgan (co-lead), Jefferies (co-lead), TD Cowen (co-lead), TD Securities (USA) LLC (co-lead)
Use of proceeds: Advancing internally developed programs, investment in its Integrated Drug Creation platform, working capital and general corporate purposes
Jul 24, 2025
Strategic investment of equity (PIPE)
Announced: US$20M
Buyers: AMD ($20 million investment)
Jan 8, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Jul 21, 2021.

Price
US$16.00 a share
Shares offered
12,500,000 shares of common stock
Offering size
US$200 million
Underwriters' option
Up to 1,875,000 more shares
Listing
ABSI on the Nasdaq Global Market
Underwriters
J.P. Morgan, Credit Suisse, BofA Securities, Cowen, Stifel · In the order on the cover
Shares delivered
On or about Jul 26, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceMay 6, 2021
Filed publiclyJun 30, 2021
Amended 4 timesNewest Jul 20, 2021
Shares registered with an exchangeJul 21, 2021
Declared effective by the SECJul 21, 2021
Final prospectus, with the priceJul 23, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Jul 23, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue2.80M4.53M5.72M5.75M4.78M4.78M2.06M
Cost of revenue11.7M62.5M47.6M58.9M44.6M11.4M4.31M
Gross profit-8.94M-57.9M-41.8M-53.2M-39.8M-6.67M2.06M
Research and development81.4M63.9M48.1M58.9M44.6M11.4M4.31M
Selling, general and administrative35.1M36.2M37.8M40.6M28.8M5.50M3.52M
Operating income-120.3M-108.9M-115.5M-106.8M-75.2M-13.3M-6.26M
Depreciation and amortization11.7M13.4M14.0M13.0M6.65M1.13M491.0K
EBITDA-108.6M-95.5M-101.5M-93.7M-68.6M-12.2M-5.77M
Interest expense209.0K565.0K1.01M972.0K3.43M634.0K268.0K
Income before tax-115.1M-103.0M-110.5M-105.4M-109.9M-14.4M-6.58M
Income tax69.0K70.0K100.0K-461.0K-8.90M0217.0K
Net income-115.2M-103.1M-110.6M-104.9M-101.0M-14.4M-6.58M
Earnings per share, basic-0.84-0.94-1.20-1.15-2.08-3.19-0.07
Earnings per share, diluted-0.84-0.94-1.20-1.15-2.08-3.19

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents20.0M41.2M72.4M60.0M252.6M69.9M13.1M
Short-term investments124.3M71.2M25.3M104.5M0
Receivables02.19M1.55M1.43M1.59M222.0K
Inventory15.0M10.5M11
Current assets149.6M133.8M120.6M186.9M273.1M73.2M13.6M
Property, plant and equipment58.0M58.7M13.4M5.01M
Goodwill021.3M21.3M0
Total assets216.3M213.6M217.3M321.0M426.2M88.6M19.5M
Accounts payable2.76M2.95M1.50M2.41M8.38M2.12M268.0K
Current liabilities22.8M28.7M29.6M30.3M33.9M10.1M3.47M
Long-term debt1.26M4.66M7.98M1.12M4.14M1.75M
Total debt5.30M3.99M7.92M10.9M3.52M14.5M6.02M
Total liabilities26.8M34.5M41.1M46.6M60.1M21.6M60.6M
Shareholders' equity189.4M179.1M176.2M274.4M366.1M-89.4M-41.2M
Shares outstanding172.7M115.4M93.1M92.4M92.6M17.9M92.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-92.9M-72.4M-64.6M-81.3M-60.6M-11.0M-6.03M
Capital spending-1.11M-404.0K-860.0K-16.2M-38.0M-2.18M-1.10M
Free cash flow-94.0M-72.8M-65.5M-97.5M-98.6M-13.2M-7.13M
Cash from investing-50.2M-41.6M81.9M-127.0M-67.4M-2.17M-1.09M
Cash from financing105.9M82.5M-4.48M5.24M336.2M71.0M12.7M
Share buybacks210.4M
Change in cash-37.1M-31.5M12.8M-203.1M208.2M57.8M5.58M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
S-3ASR · Registration statementNov 12, 2026Offer documentSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 27, 2026Big-stake noticeSEC
4 · Change in ownershipOct 14, 2026Insider tradeSEC
4 · Change in ownershipOct 14, 2026Insider tradeSEC
4 · Change in ownershipOct 14, 2026Insider tradeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K · Current reportAug 11, 2026ResultsSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
8-K · Current reportJun 24, 2026Material contractSEC
424B5 · ProspectusJun 24, 2026Offer documentSEC
8-K · Current reportJun 24, 2026Current reportSEC
4/A · Change in ownership, amendedJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
8-K · Current reportJun 5, 2026Meeting outcomeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
ARS · Annual report to shareholdersApr 22, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 22, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 22, 2026Meeting noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 14, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansMar 24, 2026Offer documentSEC
10-K · Annual reportMar 24, 2026Annual reportSEC
8-K · Current reportMar 24, 2026ResultsSEC
4/A · Change in ownership, amendedMar 16, 2026Insider tradeSEC
4/A · Change in ownership, amendedMar 16, 2026Insider tradeSEC
4/A · Change in ownership, amendedMar 16, 2026Insider tradeSEC
4/A · Change in ownership, amendedMar 16, 2026Insider tradeSEC
4 · Change in ownershipMar 16, 2026Insider tradeSEC
8-K · Current reportMar 6, 2026Material contractSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4/A · Change in ownership, amendedMar 3, 2026Insider tradeSEC
4/A · Change in ownership, amendedMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 25, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJan 30, 2026Big-stake noticeSEC
8-K · Current reportJan 14, 2026Current reportSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
8-K · Current reportNov 4, 2025Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 30, 2025Big-stake noticeSEC
4 · Change in ownershipOct 14, 2025Insider tradeSEC
4 · Change in ownershipOct 14, 2025Insider tradeSEC
4 · Change in ownershipOct 14, 2025Insider tradeSEC
4 · Change in ownershipOct 14, 2025Insider tradeSEC
4 · Change in ownershipSep 24, 2025Insider tradeSEC
4 · Change in ownershipSep 24, 2025Insider tradeSEC
4 · Change in ownershipSep 2, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveAug 25, 2025Other filingsSEC
424B3 · ProspectusAug 22, 2025Offer documentSEC
CORRESP · Letter to the SECAug 20, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 19, 2025Other filingsSEC
8-K/A · Current report, amendedAug 12, 2025ResultsSEC
S-3 · Registration statementAug 12, 2025Offer documentSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 29, 2025Big-stake noticeSEC
4 · Change in ownershipJul 29, 2025Insider tradeSEC
424B5 · ProspectusJul 25, 2025Offer documentSEC
8-K · Current reportJul 25, 2025Material contractSEC
424B5 · ProspectusJul 24, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
4 · Change in ownershipJul 9, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 9, 2025Insider tradeSEC
8-K · Current reportJul 8, 2025Management or board changeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
8-K · Current reportJun 12, 2025Meeting outcomeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 29, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 28, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2025Meeting noticeSEC
8-K · Current reportApr 28, 2025Management or board changeSEC
424B3 · ProspectusApr 11, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 11, 2025Other filingsSEC
CORRESP · Letter to the SECApr 8, 2025Other filingsSEC
UPLOAD · Letter from the SECApr 7, 2025Other filingsSEC
S-3 · Registration statementApr 1, 2025Offer documentSEC
S-8 · Registration statement for employee plansMar 18, 2025Offer documentSEC
10-K · Annual reportMar 18, 2025Annual reportSEC
8-K · Current reportMar 18, 2025ResultsSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 19, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
8-K · Current reportJan 15, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeJan 10, 2025Big-stake noticeSEC
4 · Change in ownershipDec 9, 2024Insider tradeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 18, 2024Big-stake noticeSEC
4 · Change in ownershipOct 16, 2024Insider tradeSEC
4 · Change in ownershipOct 16, 2024Insider tradeSEC
4 · Change in ownershipOct 16, 2024Insider tradeSEC
4 · Change in ownershipOct 16, 2024Insider tradeSEC
4 · Change in ownershipSep 4, 2024Insider tradeSEC
8-K · Current reportSep 4, 2024Current reportSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
8-K · Current reportAug 14, 2024ResultsSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
3 · Initial statement of ownershipJul 3, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
8-K · Current reportJun 14, 2024Meeting outcomeSEC
144 · Notice of proposed saleJun 13, 2024Other filingsSEC
4 · Change in ownershipMay 28, 2024Insider tradeSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
ARS · Annual report to shareholdersApr 23, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2024Meeting noticeSEC
4 · Change in ownershipMar 21, 2024Insider tradeSEC
S-8 · Registration statement for employee plansMar 21, 2024Offer documentSEC
10-K · Annual reportMar 21, 2024Annual reportSEC
8-K · Current reportMar 21, 2024ResultsSEC
4 · Change in ownershipMar 5, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedMar 5, 2024Big-stake noticeSEC
8-K · Current reportFeb 28, 2024Material contractSEC
424B5 · ProspectusFeb 28, 2024Offer documentSEC
8-K · Current reportFeb 27, 2024ResultsSEC
424B5 · ProspectusFeb 27, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
5 · Annual statement of ownershipFeb 14, 2024Insider tradeSEC
SC 13G · Big-stake noticeFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
8-K · Current reportJan 8, 2024Current reportSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 4, 2024Insider tradeSEC
8-K · Current reportDec 20, 2023Current reportSEC
8-K · Current reportDec 7, 2023Management or board changeSEC
8-K · Current reportDec 4, 2023Current reportSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
8-K · Current reportNov 14, 2023ResultsSEC
4 · Change in ownershipOct 16, 2023Insider tradeSEC
4 · Change in ownershipOct 16, 2023Insider tradeSEC
4 · Change in ownershipOct 16, 2023Insider tradeSEC
4 · Change in ownershipOct 16, 2023Insider tradeSEC
4 · Change in ownershipSep 6, 2023Insider tradeSEC

This page holds 200 of 364 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Absci Corporation’s releases · as of Oct 30, 2026

Common shares
172,745,810
Fully diluted
172,745,810

Fully diluted

LineSharesAs of
Common shares172,745,810Oct 30, 2026

Share count over time

CountShares
Oct 30, 2026172,745,810

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Fidelity25.7M14.9%US$277MSep 30, 2026
BlackRock14.5M8.4%US$156MSep 30, 2026
ARK11.9M6.9%US$128MSep 30, 2026
Vanguard10.3M6.0%US$111MSep 30, 2026
State Street8.46M4.9%US$91.1MSep 30, 2026
Redmile Group, LLC6.67M3.9%US$71.9MSep 30, 2026
Advanced Micro Devices Inc5.71M3.3%US$61.5MSep 30, 2026
Two Sigma5.6M3.2%US$60.3MSep 30, 2026
D. E. Shaw & Co., Inc.4.96M2.9%US$53.4MSep 30, 2026
Adage Capital Partners Gp, L.L.C.4.55M2.6%US$49MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Geode Capital4.05M2.3%US$43.6MSep 30, 2026
Ameriprise2.55M1.5%US$27.4MSep 30, 2026
Bvf Inc2.36M1.4%US$25.4MSep 30, 2026
Gem Investment Advisors, LLC2.17M1.3%US$23.4MSep 30, 2026
Baker Bros. Advisors LP2.13M1.2%US$23MSep 30, 2026
Woodline Partners LP2M1.2%US$21.5MSep 30, 2026
Marshall Wace, LLP1.95M1.1%US$21MSep 30, 2026
Nuveen1.74M1.0%US$18.7MSep 30, 2026
Goldman Sachs1.59M0.92%US$17.1MSep 30, 2026
Morgan Stanley1.43M0.83%US$15.4MSep 30, 2026
Schwab1.43M0.83%US$15.4MSep 30, 2026
UBS1.42M0.82%US$15.3MSep 30, 2026
Siren, L.L.C.1.37M0.80%US$14.8MSep 30, 2026
Northern Trust1.33M0.77%US$14.4MSep 30, 2026
Integral Health Asset Management, LLC1.3M0.75%US$14MSep 30, 2026
Fred Alger Management, LLC1.3M0.75%US$14MSep 30, 2026
Bank of America1.27M0.74%US$13.7MSep 30, 2026
Alyeska Investment Group, L.P.1.01M0.58%US$10.8MSep 30, 2026
Casdin Capital, LLC973K0.56%US$10.5MSep 30, 2026
Sumitomo Mitsui Trust Group, Inc.938K0.54%US$10.1MSep 30, 2026
Amova Asset Management Americas, Inc.938K0.54%US$10.1MSep 30, 2026
Trexquant Investment LP912K0.53%US$9.82MSep 30, 2026
Millennium769K0.44%US$8.28MSep 30, 2026
AQR Capital Management LLC735K0.43%US$7.91MSep 30, 2026
Invesco692K0.40%US$7.45MSep 30, 2026
Voloridge Investment Management, LLC657K0.38%US$7.08MSep 30, 2026
T. Rowe Price621K0.36%US$6.69MSep 30, 2026
Dimensional600K0.35%US$6.46MSep 30, 2026
Federated Hermes, Inc.599K0.35%US$6.45MSep 30, 2026
IQ EQ FUND MANAGEMENT (IRELAND) Ltd591K0.34%US$6.36MSep 30, 2026
Lazard Asset Management LLC578K0.33%US$6.23MSep 30, 2026
Renaissance Technologies548K0.32%US$5.9MSep 30, 2026
Balyasny Asset Management L.P.538K0.31%US$5.79MSep 30, 2026
Wellington515K0.30%US$5.55MSep 30, 2026
Parkman Healthcare Partners LLC479K0.28%US$5.16MSep 30, 2026
Artia Global Partners LP464K0.27%US$5MSep 30, 2026
BNY463K0.27%US$4.99MSep 30, 2026
Royce & Associates LP446K0.26%US$4.8MSep 30, 2026
Susquehanna348K0.20%US$3.75MSep 30, 2026
Barclays326K0.19%US$3.51MSep 30, 2026

This page holds 50 of 214 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
ARK Genomic Revolution ETF10.3M6.0%US$80MJul 31, 2026
Fidelity Growth Company Fund7.21M4.2%US$48.7MMay 31, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF5.17M3.0%US$59.9MJun 30, 2026
Vanguard Total Stock Market Index Fund4.41M2.6%US$51.1MJun 30, 2026
iShares Russell 2000 ETF3.55M2.1%US$41.2MJun 30, 2026
Columbia Acorn Fund2.89M1.7%US$33.5MJun 30, 2026
Columbia Small Cap Growth Fund2.27M1.3%US$15.3MMay 31, 2026
Fidelity Growth Company K6 Fund2.26M1.3%US$15.3MMay 31, 2026
Fidelity Series Growth Company Fund1.97M1.1%US$13.3MMay 31, 2026
Vanguard Extended Market Index Fund1.58M0.91%US$18.3MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Select Biotechnology Portfolio1.54M0.89%US$10.4MMay 31, 2026
Fidelity Small Cap Index Fund1.51M0.88%US$11.8MJul 31, 2026
iShares Russell 2000 Growth ETF1.07M0.62%US$12.4MJun 30, 2026
Nuveen Quant Small Cap Equity Fund975K0.56%US$7.59MJul 31, 2026
iShares Biotechnology ETF943K0.55%US$10.9MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.892K0.52%US$10.3MJun 30, 2026
Vanguard Russell 2000 Index Fund700K0.40%US$4.72MMay 31, 2026
Fidelity Extended Market Index Fund686K0.40%US$4.63MMay 31, 2026
Schwab U.S. Small-Cap ETF648K0.38%US$4.37MMay 31, 2026
Alger Small Cap Growth Fund644K0.37%US$5.01MJul 31, 2026
Columbia Variable Portfolio - Acorn Fund550K0.32%US$6.38MJun 30, 2026
iShares Micro-Cap ETF463K0.27%US$5.37MJun 30, 2026
Vanguard Explorer Fund407K0.24%US$3.17MJul 31, 2026
College Retirement Equities Fund - Total Global Stock Account365K0.21%US$4.23MJun 30, 2026
Victory Science & Technology Fund362K0.21%US$2.82MJul 31, 2026
Alger Small Cap Growth Portfolio340K0.20%US$3.94MJun 30, 2026
Schwab Small-Cap Index Fund336K0.19%US$2.61MJul 31, 2026
Invesco Dorsey Wright Healthcare Momentum ETF300K0.17%US$2.34MJul 31, 2026
Federated Hermes MDT Small Cap Growth Fund275K0.16%US$2.14MJul 31, 2026
Master Small Cap Index Series259K0.15%US$3MJun 30, 2026
Fidelity Total Market Index Fund240K0.14%US$1.62MMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF223K0.13%US$2.59MJun 30, 2026
Avantis U.S. Small Cap Equity ETF216K0.13%US$1.46MMay 31, 2026
iShares Russell 2000 Value ETF204K0.12%US$2.37MJun 30, 2026
Fidelity Series Total Market Index Fund200K0.12%US$1.35MMay 31, 2026
Alger Small Cap Growth Institutional Fund186K0.11%US$1.45MJul 31, 2026
Nuveen Small Cap Blend Index Fund183K0.11%US$1.43MJul 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares176K0.10%US$1.37MJul 31, 2026
Nuveen Equity Index Fund173K0.10%US$1.34MJul 31, 2026
Columbia Variable Portfolio - Small Company Growth Fund154K0.09%US$1.79MJun 30, 2026
EQ/2000 Managed Volatility Portfolio151K0.09%US$1.75MJun 30, 2026
Dimensional U.S. Small Cap ETF141K0.08%US$1.1MJul 31, 2026
Royce Micro-Cap Fund122K0.07%US$1.42MJun 30, 2026
Fidelity Small Cap Growth Index Fund108K0.06%US$1.25MJun 30, 2026
Dimensional U.S. Core Equity 2 ETF104K0.06%US$812KJul 31, 2026
Schwab Total Stock Market Index Fund104K0.06%US$809KJul 31, 2026
Vanguard Russell 2000 Growth Index Fund102K0.06%US$686KMay 31, 2026
Fidelity Nasdaq Composite Index Fund99,0080.06%US$668KMay 31, 2026
LVIP State Street Small-Cap Index Fund98,2000.06%US$1.14MJun 30, 2026
EQ/Small Company Index Portfolio96,4500.06%US$1.12MJun 30, 2026

This page holds 50 of 159 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Szela Mary T
Director
Buy12,900USD 11.54US$149KJun 30, 2026
Pangalos Menelas N
Director
Buy37,453USD 5.36US$201KMay 13, 2026

Big stakes

StakeStakeSharesDateFiling
FMR LLC14.40%18.4MMar 31, 2025Schedule 13G
BlackRock, Inc.7.80%13.4MSep 30, 2026Schedule 13G
Sean McClain7.20%11MSep 30, 2025Schedule 13G
ARK Investment Management LLC6.95%11.9MSep 30, 2026Schedule 13G
Redmile Group, LLC4.90%7.61MApr 10, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Eli Casdin
Other companies: GeneDx Holdings Corp. (Board Member · Since at least Apr 27, 2022); Standard BioTools Inc. (Director · Since at least Apr 4, 2022); 2Seventy Bio Inc (Director · Mar 20, 2024 – May 13, 2025 · Past); EQRx Inc (Director · Sep 30, 2022 – Sep 30, 2022 · Past); Tenaya Therapeutics, Inc. (Director · Jun 10, 2022 – Nov 17, 2022 · Past); Century Therapeutics, Inc. (Director · Jun 9, 2022 – Jun 9, 2022 · Past)
Director · Jun 8, 2022 – Jun 8, 2022 · Past
Karen McGinnis
Other companies: iRhythm Holdings, Inc. (Director · Since at least Jul 7, 2025); Alphatec Holdings, Inc. (Director · Since at least Jun 26, 2019); Sonendo, Inc. (Director · Oct 28, 2021 – Jun 16, 2023 · Past); Illumina, Inc. (VP, Chief Accounting Officer · Nov 14, 2017 – Feb 18, 2021 · Past); Cymer Inc (VP, Corporate Controller & CAO · Nov 30, 2009 – May 30, 2013 · Past); Insight Enterprises, Inc. (Chief Accounting Officer · Jan 19, 2006 – Feb 20, 2009 · Past)
Director · Since at least Jul 21, 2021
Ivana Magovčević-Liebisch
Other companies: Quanterix Corporation (Director · Since at least Oct 2, 2024); Acrivon Therapeutics, Inc. (Director · Since at least Feb 8, 2024); Vigil Neuroscience Inc (President and CEO, Director · Since at least Jan 6, 2022); Spyre Therapeutics, Inc. (Director · Jun 8, 2021 – Jun 22, 2023 · Past)
Director · Jul 21, 2021 – Jun 8, 2022 · Past
Daniel Rabinovitsj
Other companies: ARRIS International Limited (PRESIDENT, ENTERPRISE NETWORKS · Dec 1, 2017 – Mar 30, 2018 · Past); QuickLogic Corporation (Director · May 14, 2016 – Jul 15, 2022 · Past); Ruckus Wireless Inc (Chief Operating Officer · Apr 5, 2016 – May 27, 2016 · Past)
Vice President, Meta · Since at least Nov 1, 2022
Mary Szela
Other companies: Averin Capital Acquisition Corp. (Director · Since at least Feb 18, 2026); Kura Oncology, Inc. (Director · Since at least Jun 5, 2025); TriSalus Life Sciences, Inc. (CEO and President, Director · Since at least Dec 31, 2024)
President, TriSalus Life Sciences · Since at least Jul 7, 2025
Andreas Busch
Other companies: Cyclerion Therapeutics, Inc. (Chief Scientific Officer · Apr 29, 2019 – Jan 20, 2022 · Past)
Chief Innovation Officer · Since at least Mar 17, 2022
Joseph Sirosh
Other companies: Compass, Inc. (Chief Technology Officer · Mar 31, 2021 – Aug 17, 2022 · Past)
Director · Since at least Jan 7, 2022
Menelas Pangalos
Other companies: Biogen Inc. (Director · Since at least Jan 1, 2025)
Director · Since at least Jan 1, 2024
Alexander KhanCVP, Finance & Investor Relations · Since at least Oct 27, 2026
Alex KhanVPFinance & Investor Relations · Since at least Dec 11, 2025
All 30 people
PersonSeat
Amrit NagpalDirector · Jul 21, 2021 – Jun 12, 2024 · Past
Andreas PihlChief Operating Officer · Jul 21, 2021 – Jul 26, 2021 · Past
Christine LemkeSVP, Portfolio and Growth Strategy · Since at least Nov 5, 2026
ContactAlex KhanVPFinance & Investor Relations · Since at least Dec 16, 2025
Douglas Ganini da SilvaVP, Biologics Discovery & Research · Since at least Nov 5, 2026
Frans van HoutenDirector · Since at least Jun 2, 2023
Gerry MuhleChief Commercial Officer · Since at least Nov 12, 2026
Jeanne SchreuderSVP, People & Experience · Since at least Nov 5, 2026
Matthew WeinstockChief Technology Officer · Jul 21, 2021 – Feb 21, 2022 · Past
Mene PangalosSince at least Dec 12, 2024
Michael MangoneVP, Business Development · Since at least Nov 5, 2026
Moetaz AlbizemSVP, Clinical Operations · Since at least Nov 5, 2026
Ransi SomaratneChief Medical Officer · Since at least Mar 3, 2026
Sarah KormanChief Legal Officer · Jul 21, 2021 – Mar 1, 2023 · Past
Sean McClainFounder, CEO & Director · Since at least May 7, 2026
Shelby WalkerChief Legal Officer · Since at least Mar 2, 2026
Todd BedrickSVP, Chief Accounting Officer · Since at least Jul 21, 2021
Wen ShaChief of Staff · Since at least Nov 5, 2026
Zachariah JonassonCFO / CBO · Since at least Jul 21, 2021
Zach JonassonChief Financial Officer & Chief Business Officer · Since at least Dec 12, 2024

Open People

Log in to ask 6ix AI your own questions about Absci Corporation.